TrialGut2006

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

W Reinisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.